Anti-B7-H3 antibodies and methods of use thereof

Abstract

The present disclosure provides antibodies that specifically bind to B7-H3. The antibodies are useful in a variety of therapeutic, diagnostic and monitoring applications, which are also described herein. The present disclosure provides antibodies that specifically bind to B7-H3. The subject antibodies specifically bind to B7-H3 from humans and other mammals, such as monkeys and mice.

Description

[0001] cross reference [0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 870,549, filed July 3, 2019, which is incorporated by reference in its entirety. Background technique [0003] B7-H3 (also known as CD276) is a major glycoprotein expressed on the surface of antigen-presenting cells (APCs). In humans, the protein is encoded by a gene on chromosome 15. B7-H3 can inhibit the invasion of tumor cells by T cells (see, for example, Vigdorovich et al. Structure 21:707–717 and Chen et al., Exp. CellRes. 2013 319:96–102), and is therefore considered a Immune checkpoint inhibitors. The protein is from the B7 family of molecules, many of which interact with known checkpoint markers, including CTLA4, PD-1, and CD28. Both B7-H3 and PD-1 are members of the B7 / CD28 superfamily. Since both B7-H3 and PD-1 induce suppressive effects on T cells and alter their microenvironment to evade anti-tumor immune responses, B7-H3 is considered to be a simi...

AI Technical Summary

Problems solved by technology

[0004] B7-H3 is also overexpressed in many cancers, although the receptor for B7-H3 has not yet been characterized

Images